On the stock market since 1998, it operates in the world of health and science. It has 40,100 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 11% a year over the last 4 years. Every year shown ended in profit.
The gap is $2.9B. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades 51% below its peak. The market has trimmed its expectations for the company.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
Over the last 3 years, sales grew only 2% a year on average. At this size, speeding back up is not easy.
The company’s market value is 56 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, ICLR sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ICLR is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.